Trial Profile

A Study of the Safety and Efficacy of QL1706 in Combination With Chemotherapy in First-Line Treatment of Patients With Stage IIIB/C and Stage IV Non-Small Cell Lung Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 07 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bevacizumab (Primary) ; Carboplatin (Primary) ; Iparomlimab/tuvonralimab (Primary) ; Paclitaxel (Primary) ; Pemetrexed (Primary)
Indications Carcinoma; Non-small cell lung cancer; Squamous cell cancer
Focus Adverse reactions
Sponsors Qilu Pharmaceutical

Most Recent Events

02 Feb 2024 According to Qilu Pharmaceutical Media Release, this study is led by Prof. Li Zhang.
02 Feb 2024 According to Qilu Pharmaceutical Media Release, data from this study were published in Signal Transduction and Targeted Therapy.
02 Feb 2024 Results published in a Qilu Pharmaceutical Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com